ImmuneWatch Joins dIscOverNET as Associated Partner in Marie Skłodowska-Curie Doctoral Network
ImmuneWatch is proud to announce its participation as an associated partner in dIscOverNET, a newly selected doctoral network under the Marie Skłodowska-Curie Actions (MSCA) program of the European Commission.
Despite decades of global investment and the transformative impact of immunotherapy across oncology, patients with neuroendocrine tumors (NET) have seen limited progress. NETs remain a rare and difficult-to-treat cancer category, with durable disease control still out of reach for many patients. Both Europe's Beating Cancer Plan and the European Initiative on Rare Cancers have emphasized the urgent need for innovation in this space and dIscOverNET is set to answer that call.
By bringing together world-leading experts in NET biology, pioneers in immuno-oncology research, clinicians from NET expert centers, patient advocates, and representatives from the public health sector, dIscOverNET will explore whether leveraging the immune system can induce durable anti-tumor responses and ultimately help cure NETs.
As an associated partner, ImmuneWatch will contribute its expertise in TCR specificity and immune monitoring to support the network's research into T cell-based immunity in the NET tumor microenvironment. Our DETECT platform, the standard for TCR epitope annotation, is well positioned to help doctoral candidates characterise antigen-specific T cell responses and advance the understanding of immune surveillance in NET patients.
The dIscOverNET doctoral candidates will receive an interdisciplinary training program aligned with European doctoral standards, equipping them to take on leading roles across industry, academia, and government. We look forward to supporting the next generation of immuno-oncology researchers and contributing to a future where NETs can be effectively treated through immunotherapy.
The dIscOverNET Consortium
The network is coordinated by Prof. Timon Vandamme at the University of Antwerp (Belgium). The consortium brings together 10 full partners and 11 associated partners from across Europe and beyond.
Partners
- Universiteit Antwerpen — Belgium (Coordinator)
- Erasmus Universitair Medisch Centrum Rotterdam — Netherlands
- Università degli Studi di Bari Aldo Moro — Italy
- Institute of Cancer Research: The Royal Cancer Hospital — UK
- Crown Bioscience — Netherlands
- Institut National de la Santé et de la Recherche Médicale (INSERM) — France
- Universidad de Córdoba — Spain
- myNEO — Belgium
- Université Lyon 1 Claude Bernard — France
- European Molecular Biology Laboratory (EMBL) — Germany
Associated Partners
- ImmuneWatch — Belgium
- European Neuroendocrine Tumor Society (ENETS) — Germany
- SGS — Belgium
- Oncoassign — United States
- Sciensano — Belgium
- IDIBELL – Institut d'Investigació Biomèdica de Bellvitge — Spain
- International Neuroendocrine Cancer Alliance (INCA) — United States
- Orano DS — France
- Google Cloud — Netherlands
- Université Paris Cité — France
- University of London — UK
Stay up to date
Subscribe to our newsletter to receive useful tips and information.
